Lupin is currently trading at Rs. 995.00, up by 8.00 points or 0.81% from its previous closing of Rs. 987.00 on the BSE.
The scrip opened at Rs. 986.00 and has touched a high and low of Rs. 996.85 and Rs. 981.00 respectively. So far 48677 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1590.00 on 09-Sep-2016 and a 52 week low of Rs. 920.00 on 21-Aug-2017.
Last one week high and low of the scrip stood at Rs. 1008.90 and Rs. 956.90 respectively. The current market cap of the company is Rs. 44452.32 crore.
The promoters holding in the company stood at 46.70%, while institutions and non-institutions held 40.66% and 12.63% respectively.
Lupin has launched Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base). Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) are generic equivalents of Shire Development LLC’s Fosrenol Chewable Tablets 500 mg, 750 mg and 1000 mg. Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). As per IMS MAT June 2017, Fosrenol Chewable Tablets has US sales of $122.4 million.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
